Fig. 1: RTN3 is down-regulated in thyroid cancer and its low expression is associated with poor prognosis. | Cell Death & Disease

Fig. 1: RTN3 is down-regulated in thyroid cancer and its low expression is associated with poor prognosis.

From: Declined RTN3 stabilizes DHCR7 to induce cholesterol-dependent tumor progression and MEK inhibitors insensitivity in thyroid cancer

Fig. 1: RTN3 is down-regulated in thyroid cancer and its low expression is associated with poor prognosis.The alternative text for this image may have been generated using AI.

A mRNA level of RTN3 in thyroid cancer and normal tissues from TCGA database. B Relationship between RTN3 expression and pathologic T stage in thyroid cancer patients from TCGA database. C Kaplan–Meier survival analysis of progress free survival in patients with low or high RTN3 expression from TCGA-THCA cohort. D Association of RTN3 and gene set of thyroid cancer dedifferentiation (FOXE1, NKX2-1, NIS, PAX8, TG, TPO and TSHR). E Representative IHC staining images of RTN3 (left) and relative expression levels (right) in 45 pairs of thyroid cancer and adjacent normal tissues (scale bar, 100 μm). F, G qRT-PCR (F) and WB (G) detected mRNA and protein expression levels of RTN3 in normal thyroid and thyroid cancer cell lines. H, Validation of RTN3 knockout by WB. I–K Cell proliferation ability after RTN3 knockout determined by colony-formation assays (I), CCK-8 assays (J) and EdU assays (K) with representative images in the left (scale bar, 40 μm) and the quantification of EdU positive cell ratios in the right, n = 3. L, M Cell migration ability after RTN3 knockout determined by transwell assays (L) (scale bar, 40 μm) and wound healing assays (M) (scale bar, 100 μm), with representative images in the left and the quantification graphs in the right, n = 3. *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001.

Back to article page